{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.36075","value":"-0.1741"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"Bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.32985","value":"5.8734"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"Creatinine"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.35650","value":"0.0306"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"title":"Direct Bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.90174","value":"5.7897"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Urate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Change from baseline in Chemistry laboratory analysis. Includes Bilirubin, Creatinine, Direct Bilirubin, and Urate. Baseline is the last observation collected prior to or on the date of product infusion.","dispersionType":"Standard Deviation","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEAN","populationDescription":"All participants who received at least one JCAR017 infusion evaluable for chemistry laboratory tests","reportingStatus":"POSTED","timeFrame":"Baseline and Day 29","title":"Change From Baseline of Chemistry Laboratory Results: Bilirubin, Creatinine, Direct Bilirubin, Urate","type":"SECONDARY","unitOfMeasure":"umol/L"}